Best Stocks to Invest in Alzheimer's Research in 2021
Biogen Stock Is Rising—Will the Gains Continue after the FDA's Alzheimer’s Drug Decision?
S&P 500’s Top Losses: Why Biogen Declined
Biogen, which is an American multinational biotechnology company, was the S&P 500’s top loss on June 18.
A Look at Sarepta Therapeutics’ Stock Performance
After its stellar rise from $54.02 on January 8 to a high of $161.51 on September 28, Sarepta stock has seen selling pressure amid the market volatility in October.
Biogen’s Experimental Alzheimer Therapy: Limited 2Q15 Success
On July 22, 2015, Biogen (BIIB) released data from a Phase 1b study, also called the PRIME Study, that looked at the effectiveness of its investigational Alzheimer’s drug, BIIB037.
A Look at Ionis’s Revenue Streams in the Second Quarter
Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.
How Gilead Sciences’ Gross Margin Outshines Its Peers
Despite a year-over-year (or YoY) drop in revenues in 2Q16, Gilead Sciences (GILD) managed to earn gross margins of about 92%.
Regeneron Continues to Trade at Premium
Regeneron is consistently trading at a premium compared to its peers. As of January 22, it was trading at a valuation multiple of 26.67x its earnings.
Amgen Continues to Control Operating Expenses in 3Q15
In 3Q15, Amgen recorded total operating expenses of ~$3.4 billion. This fall in expenses enabled the company to report a net profit margin of ~36.4%.
What Analysts Recommend for Biogen in June 2017
In 2016, Biogen (BIIB) reported revenues of $11.4 billion, which reflected a ~6% year-over-year (or YoY) growth.
Must-Read: Amgen’s 3Q15 Earnings and Conference Call
In its 3Q15 earnings report released on October 28, Amgen reported YoY revenue growth of ~14.0%, from $5.0 billion in 3Q14 to $5.7 billion in 3Q15.
How 3Q17 Shaped up for Tysabri, Fampyra, and Zinbryta
Tysabri revenue trends In 3Q17, Biogen’s (BIIB) Tysabri generated revenue of ~$469 million, which reflected a ~9% fall YoY (year-over-year) and a ~5% fall QoQ (quarter-over-quarter). In 3Q17, Tysabri generated US revenue of ~$267 million, which reflected an ~11% fall YoY and an ~8% fall QoQ. In 3Q17, outside the US market, Tysabri reported revenue of ~$203 […]
How Biogen’s Tysabri and Zinbryta Performed in 1Q17
In 1Q17, Biogen (BIIB) saw an increased demand for Tysabri, both in the United States and in international markets.
Biogen: S&P 500’s Top Loser on January 8
Biogen was the S&P 500’s top loser on January 8. Biogen regained strength last week and rose to ten-week high price levels.
How BioMarin Pharmaceutical Is Positioned Financially in August
In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017.
Analysts Expect Biogen’s Net Profit Margins to Rise in 3Q15
Biogen’s (BIIB) 3Q15 earnings results will be announced on October 21, 2015. Analysts expect that the company will report lower net profit margins as compared to 2Q15.
Third Point Partners ups stake in Amgen
The fund noted in its letter that “Amgen has all the hallmarks of a hidden value situation, which is one of the fund’s favorite investment themes.”
Biogen Pursuing Investigational Candidates in Alzheimer’s Disease
Biogen (BIIB) has entered into a licensing agreement with Bristol-Myers Squibb (BMY) for exclusive global rights for the development and commercialization of BMS-986168.
What Analysts Think about Ionis
In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.
Investor Insights: Teva Pharmaceutical’s Valuation Multiples
On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x.
Teva Is Expected to See a Fall in Its Profit Margins in 2017
Teva Pharmaceutical (TEVA) expects its 2017 non-generally accepted accounting principles (non-GAAP) earnings per share (or EPS) to fall in the range of $4.9–$5.3.
What’s behind Biogen Buyout Rumors?
Since early August 2016, there have been rumors of a likely buyout of Biogen (BIIB) by one of the many interested suitors in the biotechnology industry.
Analyzing Johnson & Johnson’s 1Q18 Profitability
Johnson & Johnson (JNJ) reported revenues of $20.0 billion during 1Q18, 12.6% growth as compared to revenues of $17.8 billion during 1Q17.
Regeneron’s Stock Reacts to Dupilumab Phase 3 Trials
Regeneron Pharmaceuticals (REGN) rose 9.3% during the week ending April 1, 2016.
Biogen Trades at High Valuation Multiples Due to Strong Research Pipeline
After the release of its 3Q15 earnings results on October 21, Biogen was trading at PE multiples in the range of 13.8x–15.3x.
Biogen’s Interferon Therapies Could Witness Modest Fall in 2017
In 2016, Biogen’s (BIIB) interferon therapies, Avonex and Plegridy, together reported revenues of around $2.8 billion, which reflected a drop of ~6% on a year-over-year (or YoY) basis.
What’s Gilead Sciences’ Valuation?
Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.
Could Baxalta Maintain Its Leadership in the Hemophilia Space?
Baxalta’s (BXLT) hemophilia portfolio comprises of Advate, Adynovate, Rixubis, Recombinate, Hemofil M, Immunate, Immunine, and Prothromplex Total.
What Will Be a Key Driver of Biogen’s Future Valuations?
Biogen’s investigational Alzheimer’s disease drug, aducanumab, is one of the four therapies accepted in the EMA’s Priority Medicines program (or PRIME).
What Are the Current Treatment Options for Hemophilia?
Hemophilia treatment primarily includes factor replacement therapy and prolonged half-life therapy such as factor VIII or factor IX infusion.
BMN 270: A Big Valuation Catalyst for BioMarin
On March 1, 2016, BioMarin received orphan drug designation for BMN 270 from the FDA. BioMarin’s stock jumped by about 6.96% the same day.
How Much Does Biogen Spend on Research and Development?
Biogen’s (BIIB) R&D expenses for 4Q15 were $542 million, or 19% of its total revenue, including a $60 million payment to Mitsubishi Tanabe.
Novartis’s 3Q16 Estimates: Innovative Medicines Segment
Novartis’s Innovative Medicines segment, formerly referred to as the Pharmaceutical segment, consists of products for a variety of therapeutic areas.
Biogen Stock Trending Higher on Strong Q2 2018 Results
Today, Biogen (BIIB) announced its earnings results for the second quarter of fiscal 2018. Here’s what you need to know.
Novartis’s 4Q16 Estimates: Innovative Medicines Segment
The overall contribution of the Innovative Medicines segment is ~67% of Novartis’s total revenues.
Allergan’s 1Q18 Earnings: Analysts’ Estimates
Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.
BIIB Stock Tumbles as Alzheimer Drug BAN2401 Data Failed to Impress Investors
Today, Biogen (BIIB) and partner Eisai presented highly anticipated detailed study data for their investigational Alzheimer’s drug BAN2401.
Why the US Moat Index Beat the S&P 500 Index in July
Domestic moat companies, as represented by the Morningstar® Wide Moat Focus IndexSM (MWMFTR, or “U.S. Moat Index”), once again posted strong results in July.
Why Sesen Bio Stock Jumped Over 37% this Week
Sesen Bio (SESN), formerly known as Eleven Biotherapeutics, is developing next-generation antibody-drug conjugate therapies. The stock jumped ~26.1% to $2.27 yesterday.
Biogen Stock Surges 44 Percent on FDA Review for Alzheimer’s Drug
Gilead Sciences’ Valuation Continues to Lag behind Peers
Post 2014, Gilead Sciences has traded at lower valuation multiples, as investors are uncertain of the company’s ability to continue its leadership in the global HIV market.
What Biogen Is Doing that Put It in Good Favor with Analysts
Based on recommendations from 25 broker companies, a Bloomberg survey reported that 62.5% of analysts gave Biogen (BIIB) “buy” recommendations.
Gilead Sciences in 4Q15: Analysts Project Modest Revenue Growth
On February 02, 2016, Gilead Sciences will announce its 4Q15 earnings for the period ending December 31, 2015. Analysts expect modest revenue growth.
What Are Analysts Estimating for Allergan Today?
AGN’s analysts estimate EPS of $4.72 on revenues of $4.27 billion for 4Q17, which would be 10.5% higher YoY (year-over-year).
Celgene’s Operating Expenses in 3Q15
In 3Q15, Celgene’s gross profit margin improved due to a favorable product mix composed mainly of Revlimid, Pomalyst, and Otezla.
Inside AbbVie’s Analyst Recommendations in 2016
Based on 24 recommendations, Bloomberg reported that 59.1% of analysts gave AbbVie a “buy” recommendation, while 36.4% of analysts gave the stock a “hold.”
Celgene Estimates Robust Revenue in 2017
In 2017, Celgene (CELG) expects to earn revenues of $13.0 billion–$13.4 billion, which would be a YoY (year-over-year) growth of around 18.0%.
BeiGene’s Q2 2018 Earnings: Reports Revenue Growth
BeiGene (BGNE) released its Q2 2018 earnings on August 9. BGNE surpassed analysts’ estimates for revenues but missed its EPS estimates.
Renaissance Technologies: Analyzing Its Q3 13F
At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.
How Is Biogen’s Tecfidera Positioned in 2019?
In the first quarter, Biogen reported multiple sclerosis franchise revenue of ~$2.1 billion, a flat performance on a YoY (year-over-year) basis.
Dalio’s Bridgewater: Major Stocks Positions and New Buys in Q1
Biogen (BIIB) was Bridgewater’s largest stock holding. Biogen contributed 0.35% of the fund’s total holdings.
Do Analysts See Any Upside for Vertex Stock?
Of the 25 analysts covering Vertex Pharmaceuticals (VRTX), 21 recommend “buy” or a higher rating, and four recommend “hold.”
Vertex Pharmaceuticals’ Gross Margin Trends
Kalydeco, Orkambi, and Symdeko are Vertex Pharmaceuticals’ (VRTX) products on the market.
Sage Therapeutics’ Operational Performance
In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively.
Sage Therapeutics: Analyzing New Product Candidates
The Zulresso injection is Sage Therapeutics’ lead product candidate. The company has filed a new drug application.
Do Analysts See Any Upside for Regeneron Stock?
Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.”
Regeneron Pharmaceuticals’ Gross Margin Trends
In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017.
Taking Stock of Sangamo’s Financial Performance
In this series, we explore Sangamo’s financials, analysts’ views on the stock, and the company’s valuation metrics.
United Therapeutics: Recent Developments and Analysts’ Ratings
On November 15, United Therapeutics (UTHR) entered into a global license agreement with Arena Pharmaceuticals (ARNA).
Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings
Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion.
Recommendations for Shire as of October 30
Analysts’ estimates show that Shire (SHPG) stock has a potential to return ~15.8% over the next 12 months.
Amgen: Analysts’ Recommendations on October 25
Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter.
Amgen: Expect Nearly Flat Revenues in Q3
New products are expected to deliver double-digit growth, while legacy brands are expected to offset the growth during the quarter.
Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth
Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.
Biogen: Analysts’ Recommendations on October 19
For Biogen, eight analysts recommended a “strong buy,” 12 recommended a “buy,” and nine recommended a “hold.”
Biogen: Revenue Growth Is Expected in Q3
Interferon contributed ~18% of Biogen’s total revenues. Analysts expect the revenues to decrease during the third quarter.
Analyzing Sarepta’s Product Pipeline
Sarepta is expected to incur R&D expenses of $277.8 million in fiscal 2018, compared with $166.71 million in fiscal 2017.
Celgene’s Financial Position before Its Third-Quarter Earnings
Celgene is expected to report its third-quarter earnings on October 25. Celgene is expected to generate revenues of $3.8 billion in the third quarter.
Allergan’s Stock Performance and Estimates for Q3 2018
Wall Street analysts expect Allergan to report EPS of $3.98 on revenues of $3.8 billion in the third quarter.
Ionis Pharmaceuticals’ Revenue Growth Rate
Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018.
Ionis Pharmaceuticals’ Stock Performance in September
On September 28, Ionis Pharmaceuticals received one “strong buy” rating, three “buy” ratings, seven “hold” ratings, and two “sell” ratings.
Eli Lilly’s Earnings Quality and Dividend Performance
Eli Lilly’s dividend yield is 2.11%. Its dividend yield last year was 2.46%, and its five-year average is 2.77%.
Allergan’s SpotLyte and Lumivive System
SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.
Allergan’s Developments in September
On September 20, Allergan (AGN) announced a partnership with actor Scott Eastwood to encourage the recognition of World Alzheimer’s Day on September 21.
How Analysts View BioMarin Pharmaceutical in August
On August 30, 2018, BioMarin Pharmaceutical (BMRN) stock closed at $99.26 which is 7% below its 52-week high of $106.20 on August 2.
Examining Amgen’s Revenue Trend in Q2 2018
Amgen reported a 4% rise in its year-over-year revenue to ~$6.06 billion in the second quarter compared to $5.81 billion in the first quarter of 2017.
Analyst Recommendations for Biogen and Its Peers in August
On July 25, Biogen (BIIB) and Eisai announced positive results from the Phase 2 study evaluating BAN2401 in early Alzheimer’s disease.
Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth
Sarepta Therapeutics (SRPT) released its Q2 2018 earnings on August 8, surpassing analysts’ estimates for EPS and revenues.
Analysts Are Bullish on Sarepta Therapeutics
Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in Q1 2018.
What to Expect from Sarepta’s Second-Quarter Earnings
Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.
What Do Analysts Expect from Ionis’s Q2 2018 Earnings?
Ionis is expected to report 30.0% growth in revenues to $135.5 million in the second quarter of 2018 as compared to $104.2 million in Q2 2017.
Shire’s Q2 2018 Earnings Beat Analyst Estimates
Shire (SHPG) beat Wall Street analysts’ estimates for revenues and EPS. It reported non-GAAP EPS of $3.88 on revenues of $3.9 billion in Q2 2018.
What to Expect from Shire’s Q2 2018 Earnings on July 31
Shire (SHPG) is set to release its Q2 2018 earnings on July 31. Wall Street analysts expect EPS of $3.67 on revenues of $3.8 billion.
Amgen Beats Estimates, Reports Growth in Q2 2018
Amgen (AMGN) reported in Q2 2018 results yesterday, surpassing analysts’ EPS and revenue estimates.
Amgen Announced the Phase 3 Results for ABP 710
On June 27, Amgen (AMGN) announced the top-line results for the NCT02937701 study—a Phase 3 study evaluating safety and efficacy of ABP 710.
Risdiplam: Could It Be PTC Therapeutics’ Future Growth Driver?
In June, PTC Therapeutics (PTCT) presented its updated interim clinical data from the Phase 1 FIREFISH trial.
Biogen and Ionis Crash on PTC Therapeutics’ Promising Data
Yesterday, PTC Therapeutics (PTCT) registered a stock price rise of ~24.6% on the positive data the company presented along with partner Roche (RHHBY) for their SMA (spinal muscular atrophy) drug risdiplam.
Intellia Therapeutics Stock Fell 9.8% on Monday
On June 11, Intellia stock fell 9.8% to close at $24.56 over concerns of the CRISPR-CAS9 Gene Therapy.
Why Axovant Sciences Stock Jumped ~160% on Wednesday
Axovant Sciences (AXON) stock jumped ~160.0% to the closing price of $4.55 on June 6.
Gilead Sciences’ Valuation in March 2018
Gilead Sciences surpassed analysts’ estimates and reported an EPS of $1.78 on revenues of $5.9 billion during 4Q17.
Exploring Alkermes’ Financial Performance in Fiscal 2017
Alkermes (ALKS) generated total revenues of $903.0 million in fiscal 2017 compared with $745.6 million in fiscal 2016.
A Look at Alkermes’ Diabetes Product Portfolio
According to Alkermes, ~26.0 million people in the US and 382.0 million people globally are affected by diabetes.
Performance of Johnson & Johnson’s Remicade and Stelara in 2017
In fiscal 2017, Johnson & Johnson’s (JNJ) blockbuster drug Remicade generated revenues of $6.3 billion, which reflected an ~9.3% decline year-over-year.
Biogen: S&P 500’s Top Loser on February 14
Biogen, which is an American multinational biotechnology company, was the S&P 500’s top loser on February 14.
Exploring Bioverativ’s Business Profile and Market Presence
Bioverativ completed its spin-off from Biogen (BIIB) in February 2017. Bioverativ is expected to register 30% growth in 2017.
How Biogen’s Biosimilars and Interferons Performed in 4Q17
In 4Q17, Biogen’s (BIIB) interferons generated revenues of $645 million, which reflected a 6% decline YoY and a 3% decline on a quarter-over-quarter basis.
How Biogen’s Spinraza Is Positioned for 2018
In 4Q17, Biogen’s (BIIB) Spinraza generated revenues of $363 million, which reflected 34% quarter-over-quarter growth.
Merck & Co.’s Quarterly Revenue Trend
Merck & Co. (MRK) reported revenues of $10.3 billion in 3Q17, a decrease of 2% compared to 3Q16.
Developments for Ionis Pharmaceuticals Post-3Q17
Ionis Pharmaceuticals (IONS) is focused on the development of drugs for the treatment of diseases with limited or nontherapeutic options.
Exploring Ionis’s 3Q17 Quarterly Revenue Trend
Ionis’s revenue sources include its commercial revenue and its research and development revenue under its collaborative agreements.